ZOFRAN
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOFRAN (ondansetron) is an oral tablet small-molecule antiemetic approved in 1992 for prevention and treatment of nausea and vomiting. It is a selective 5-HT3 receptor antagonist widely used across oncology, post-operative, and chemotherapy-induced nausea and vomiting (CINV) settings. The drug has become a standard-of-care agent in multiple therapeutic areas.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), indicating a mature, commoditized market with limited growth opportunities and potential team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women
Started Mar 2006
515 enrolled
Nausea and Vomiting, PostoperativePostoperative Nausea and Vomiting
Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women
Started Mar 2006
482 enrolled
Nausea and Vomiting, Postoperative
Career Relevance
ZOFRAN roles are shrinking as the product enters post-LOE maturity under Novartis ownership. Career opportunities focus on managed-care negotiation, generic competition defense, and niche indication development rather than commercial growth.
Brand Manager
Worked on ZOFRAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.